ONUREG
RegisteredCombined Mark
•
Ownership
CC
Owner Name
Type: Organization / Corporation
Address
86 Morris Avenue
Summit, NJ 07901
Critical Dates
First Use Date
Sep 1, 2020
Filing Date
Sep 25, 2018
Registration Date
Nov 23, 2021
Mark Descriptions
Goods
Class 5
Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease and cancer
Mark Elements
Text Mark
ONUREG
Category
Trademark
Standard Characters
No
Color Claim
Yes
Drawing/Image Description
The mark consists of overlapping purple circles with 4 dots with white centers, the first two and last dots are in blue and white and the second dot is yellow and white dots with the word "ONUREG" in blue to the right.
Color Details
The color(s) blue, purple, white and yellow is/are claimed as a feature of the mark.
Design Search Codes
26.01.16
Circles touching or intersecting26.01.31
Circles - five or moreData source: USPTO TSDR
View on USPTO websiteTrademark Timeline
First Use
Filing Date
Publication Date
Registration Date
USPTO Records
| Title | Date | Category | Source | Pages | Format | Actions |
|---|---|---|---|---|---|---|
AI AssessmentCached Mar 12, 2026, 06:06 AMCached
AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.
Trademark Summary
The mark ONUREG features overlapping purple circles with blue, white, and yellow dots alongside the word ONUREG in blue, covering pharmaceutical preparations, namely, cytokine inhibitory drugs, immune system modulators, and treatments for blood disease and cancer in class 005, plus classes 006, 018, 044, 046, 051, and 052. It is owned by Celgene Corporation, a Delaware corporation headquartered in Summit, New Jersey. The mark is registered on the Principal Register (Reg. No. 6569697) since November 23, 2021, with first use in commerce on September 1, 2020. No active oppositions or legal proceedings are present.
Recent Activity
Filed on September 25, 2018, the application faced a non-final office action in November 2018, was published for opposition on February 5, 2019, and issued a Notice of Allowance in April 2019. After multiple extensions of time to file a Statement of Use (up to the fifth), the Statement of Use was accepted in October 2021, leading to registration on November 23, 2021.
USPTO
AI Analysis
v2.8.0
Never miss important updates for this trademark
Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach